Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 6/20 | 0.60 |
| ▸ | DUT | P33316 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | POLD1 | P28340 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15139316 | 1.00 | TYMS (0.60) | TYMSDUTPOLBPOLA1POLD1 | |
| SCHEMBL16728018 | 0.91 | POLB (0.58) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL15139311 | 0.91 | POLB (0.58) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL1666080 | 0.91 | POLB (0.58) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL16728017 | 0.91 | TYMS (0.64) | TYMS | |
| SCHEMBL15139310 | 0.91 | TYMS (0.64) | TYMS | |
| SCHEMBL1665942 | 0.91 | TYMS (0.64) | TYMS | |
| SCHEMBL15139309 | 0.89 | POLB (0.57) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL1665279 | 0.89 | POLB (0.57) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL16728005 | 0.89 | POLB (0.57) | TYMSPOLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200319-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150140559-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8877905-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | TYMS 35/4885DUT 7/4885POLB 24/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | TYMS 35/4885DUT 7/4885POLB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.